Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.36 |
| ▸ | KCNT1 | Q5JUK3 | 2/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2257612 | 0.81 | RXRA (0.43) | RXRANR1H2NR1H3CARM1KLKB1 | |
| SCHEMBL2260461 | 0.79 | CARM1 (0.50) | RXRANR1H2NR1H3CARM1GPBAR1 | |
| SCHEMBL15706914 | 0.78 | KLKB1 (0.39) | RXRANR1H2NR1H3CARM1KLKB1 | |
| SCHEMBL2257699 | 0.76 | RAB9A (0.46) | RXRANR1H2NR1H3CARM1KCNT1 | |
| SCHEMBL3473146 | 0.76 | RXRA (0.51) | RXRANR1H2NR1H3TRPM8GPBAR1 | |
| SCHEMBL2257738 | 0.75 | RXRA (0.44) | RXRANR1H2NR1H3CARM1KLKB1 | |
| SCHEMBL950585 | 0.73 | KLKB1 (0.52) | RXRANR1H2NR1H3CARM1KLKB1 | |
| SCHEMBL2259509 | 0.73 | CYP11B2 (0.51) | CARM1KLKB1 | |
| SCHEMBL2255810 | 0.73 | CARM1 (0.43) | RXRANR1H2NR1H3CARM1TGFBR1 | |
| SCHEMBL2256089 | 0.73 | KLKB1 (0.41) | KLKB1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121621-B1 | LXR AND FXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2008073825-A1 | LXR AND FXR MODULATORS | EXELIXIS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069367-A1 | LXR and FXR Modulators | NR1H3, NR1H2, NR1H4 | RXRA 8/4885NR1H2 2/4885NR1H3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.